Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
130 hedge funds and large institutions have $475M invested in Orexigen Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
72% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $6.81M
21% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 39
8% more capital invested
Capital invested by funds: $442M → $475M (+$33.2M)
6% more funds holding
Funds holding: 123 → 130 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.82M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.65M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.46M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$7.14M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$6.96M |
| 3 |
First Manhattan
New York
|
-$6.05M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.76M |
| 5 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$2.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
126
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
MFS
127
MSI Financial Services
Springfield,
Massachusetts
| $1K | – | – | – |
|
|
PAS
128
Partnervest Advisory Services
Santa Barbara,
California
| $1K | – | – | – |
|
|
PTC
129
Private Trust Company
Cleveland,
Ohio
| $1K | – | – | – |
|
130
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $459 | -$19.8K | -293 | -4% |
|
|
RG
131
Redmile Group
San Francisco,
California
| – | -$6.96M | -119,044 | Closed |
|
|
GC
132
Guggenheim Capital
Chicago,
Illinois
| – | -$1.82M | -31,166 | Closed |
|
133
Nomura Holdings
Tokyo,
Japan
| – | -$359K | -6,124 | Closed |
|
|
ROTUOC
134
Regents of the University of California
Oakland,
California
| – | -$247K | -4,220 | Closed |
|
135
TD Asset Management
Toronto,
Ontario, Canada
| – | -$175K | -2,990 | Closed |
|
|
HLA
136
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$86K | -1,477 | Closed |
|
137
Envestnet Asset Management
Chicago,
Illinois
| – | -$2K | -30 | Closed |
|
|
JG
138
Jefferies Group
New York
| – | -$1K | -14 | Closed |
|
OREX Hedge Fund Activity: Q3 2013 in Review
130 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2013, worth a combined $475M — up 7.5% from $442M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OREX positions and 8 closed out — a net gain of 9 holders — while 47 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.4M. The largest seller was Visium Asset Management, cutting an estimated $7.14M.
- 130 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2013, up from 123 in Q2 2013.
- Funds reported $475M of Orexigen Therapeutics, Inc. stock for Q3 2013, up 7.5% quarter-over-quarter.
- 17 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2013 and 8 closed out, a net change of +9 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q3 2013 was Fidelity Investments, an estimated $12.4M added.
- The largest Orexigen Therapeutics, Inc. seller in Q3 2013 was Visium Asset Management, an estimated $7.14M sold.
Based on aggregated 13F filings for Q3 2013.